Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer by unknown
RESEARCH Open Access
Epigenetic reactivation of estrogen receptor-α
(ERα) by genistein enhances hormonal therapy
sensitivity in ERα-negative breast cancer
Yuanyuan Li1,3*, Syed M Meeran7, Shweta N Patel6, Huaping Chen1, Tabitha M Hardy1
and Trygve O Tollefsbol1,2,3,4,5
Abstract
Background: Estrogen receptor-α (ERα)-negative breast cancer is clinically aggressive and normally does not
respond to conventional estrogen target-directed therapies. The soybean isoflavone, genistein (GE), has been
shown to prevent and inhibit breast cancer and recent studies have suggested that GE can enhance the anticancer
capacity of an estrogen antagonist, tamoxifen (TAM), especially in ERα-positive breast cancer cells. However, the role
of GE in ERα-negative breast cancer remains unknown.
Methods: We have evaluated the in vitro and in vivo epigenetic effects of GE on ERα reactivation by using MTT
assay, real-time reverse transcription-polymerase chain reaction (RT-PCR) assay, western-blot assay,
immunoprecipitation (ChIP) assay, immunohistochemistry and epigenetic enzymatic activity analysis. Preclinical
mouse models including xenograft and spontaneous breast cancer mouse models were used to test the efficacy of
GE in vivo.
Results: We found that GE can reactivate ERα expression and this effect was synergistically enhanced when
combined with a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), in ERα-negative MDA-MB-231 breast
cancer cells. GE treatment also re-sensitized ERα-dependent cellular responses to activator 17β-estradiol (E2) and
antagonist TAM. Further studies revealed that GE can lead to remodeling of the chromatin structure in the ERα
promoter thereby contributing to ERα reactivation. Consistently, dietary GE significantly prevented cancer
development and reduced the growth of ERα-negative mouse breast tumors. Dietary GE further enhanced
TAM-induced anti-cancer efficacy due at least in part to epigenetic ERα reactivation.
Conclusions: Our studies suggest that soybean genistein can epigenetically restore ERα expression, which in turn
increases TAM-dependent anti-estrogen therapeutic sensitivity in vitro and in vivo. The results from our studies
reveal a novel therapeutic combination approach using bioactive soybean product and anti-hormone therapy in
refractory ERα-negative breast cancer which will provide more effective options in breast cancer therapy.
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Background
Breast cancer is the most common type of cancer and
the second leading cause of death among women in the
United States. The principle therapeutic strategy for
breast cancer involves surgical removal of the primary
tumor following extensive radiotherapy and chemother-
apy. Several clinical trials have suggested that estrogen
ablation or anti-estrogen strategy is effective in the pre-
vention or treatment of breast cancer, especially in estro-
gen receptors (ERs)-dependent breast cancer [1-3].
There are two major isoforms of ERs (ERα and ERβ) that
have been identified and the ERα isoform is believed to
primarily contribute to estrogen-induced growth stimu-
latory effects in breast cancer [4]. Estrogens binding to
ERs result in activated signaling pathways leading to cel-
lular proliferation and differentiation in normal mam-
mary tissue. However, aberrant activation of estrogen-ER
signaling renders unlimited and uncontrolled cell prolif-
eration which occurs in most breast tumors [5-7]. The
estrogen antagonist, tamoxifen (TAM), is currently the
first-line medical treatment for ERα-positive breast can-
cer at all stages of this disease in both pre- and postme-
nopausal women [8]. TAM has also been shown to have
potential benefit for the prevention of breast cancer
among women at high risk of breast cancer [1]. How-
ever, ERα-negative breast cancers do not respond to
TAM treatment and generally have a more clinically ag-
gressive progression resulting in a poorer prognosis [9].
Extensive studies have shown that the major cause for
inactive ERα signaling is the absence of ERα gene ex-
pression. Although the precise mechanisms of ERα tran-
scription regulation are still under investigation, it has
been clear that acquired loss of ERα transcription rather
than a genetic alteration such as DNA mutations is a
potential mechanism for hormone resistance in ERα-
negative breast cancer [10]. Recent studies indicate that
epigenetic mechanisms, which primarily involve two path-
ways, DNA methylation and histone modification, may
play a crucial role in regulating ERα expression [11-14].
Supportive evidence has included intervention application
of epigenetic modulators such as DNA methyltranferase
(DNMT) inhibitor, 5-aza-2’-deoxycytidine (5-aza), and his-
tone deacetylase (HDAC) inhibitor, trichostatin A (TSA),
which successfully induced ER expression and sensitized
hormone-resistant ERα-negative breast cancer cells to
chemotherapy [13-16]. In this regard, it is increasingly evi-
dent that epigenetic events play an important role in ERα
gene expression.
Despite a high incidence and mortality by breast can-
cer in the United States and Europe, Asian women who
consumed 20–50 times more soy products per capita
than their western counterparts have much less suscepti-
bility to developing breast cancer [17-19]. Soybean prod-
uct is a rich source of genistein isoflavone, which is
believed to be a potent botanical chemopreventive com-
pound against various types of cancers, including breast
cancer [20]. Genistein (GE) exerts its anti-cancer proper-
ties through various mechanisms such as anti-oxidation,
induction of apoptosis and differentiation as well as in-
hibition of angiogenesis and proliferation [21-24]. One
potential mechanism that has recently received consider-
able attention is that GE may regulate gene transcription
by modulating epigenetic events [25-27]. This hypothesis
is supported by studies showing that dietary GE causes
epigenetic changes in mouse prostate [28]. Our studies
as well as others have also suggested an epigenetic
associated-prevention role of GE by regulating key
tumor-related genes such as p16INK4a and the human
telomerase reverse transcriptase (hTERT) gene, leading
to tumor prevention and suppression in malignant
human mammary cells [26,29]. More importantly, stud-
ies have shown that GE treatment can enhance or
sensitize the preventive and inhibitory effects of TAM in
ERα-positive breast cancer cells [30,31]. However, the
potential impact of GE on the estrogen-ERα pathway
and the further combination effect of GE with TAM on
ERα-negative breast cancer have not been well defined
experimentally. Since TAM is widely used for prevention
and treatment for breast cancer and soy products are
recognized as important bioactive components against
breast cancer, it is imperative to define the interactive ef-
fect between soy components and TAM on breast can-
cer prevention, especially on intractable hormone-
resistant breast cancer.
We therefore hypothesize that GE might epigenetically
reactivate ERα which may facilitate TAM-mediated es-
trogen-dependent therapy by resensitizing ERα-negative
breast cancer cells. Our studies used both in vitro and
in vivo approaches to investigate the epigenetic effects of
soybean GE on ERα reactivation and how this change
may affect cell sensitivity to conventional anti-hormone
agents such as TAM in hormone-resistant breast cancer.
Our findings help to develop a novel combination ap-
proach by using soybean product and hormone antago-
nists for chemoprevention and therapeutic strategies in
estrogen-resistant breast cancers.
Materials and methods
Cell culture and cell treatment
Breast cancer cell lines including ERα-positive MCF-7
and ERα-negative MDA-MB-231 and MDA-MB-157
cells as well as normal human mammary epithelial cells
(HMECs) were obtained from American Type Culture
Collection (ATCC) and Lonza (Basel, Switzerland), re-
spectively. Breast cancer cells were grown in phenol-
red–free medium DMEM (Invitrogen, Carlsbad, CA)
supplemented with 10% dextran-charcoal–stripped fetal
bovine serum (Atlanta Biologicals, Lawrenceville, GA)
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and 1% penicillin/streptomycin (Mediatech, Herndon,
VA). HMECs were grown in serum-free Mammary Epi-
thelial Growth Medium (MEGM) without sodium bicar-
bonate accompanied with MEGM SingleQuots (Lonza)
at 37°C and 0.1% CO2. Breast cancer cells were main-
tained in a humidified environment of 5% CO2 and
95% air at 37°C. To evaluate ERα expression, attached
MDA-MB-231 and MDA-MB-157 cells were treated
with various concentrations of genistein (GE) (Sigma, St.
Louis, MO) for 3 days while MCF-7 cells served as a
positive control. The medium with GE was replaced
every 24 h for the duration of the experiment. Control
cells received equal amounts of DMSO (Sigma) in the
medium. For the combination study, cells were treated
with an optimal concentration (25 μM) of GE based on
our results and 5-aza (2 μM for 2 days) (Sigma) or TSA
(100 ng/ml for 12 h) (Sigma) alone or together for a total
3 days as common recommended doses of these com-
pounds [32]. HMECs were used as a normal control to
evaluate potential toxicity in response to GE and/or TSA
treatment. To observe the effects of 17β-estradiol (E2)
(Sigma) and tamoxifen (TAM) (Sigma) on ERα expres-
sion, GE and/or TSA-pretreated MDA-MB-231 cells
[GE at 25 μM for 3 days or TSA at 100 ng/ml for 12 h
for single treatment, and GE (25 μM for 2 days) + TSA
(100 ng/ml for 12 h) for combination treatment] were
then exposed with or without 10 nM of E2 or 1 μM
TAM for an extra two days, respectively.
MTT assay for cell viability
To determine the effects of GE alone or in combination
with TSA on cell viability when exposed with E2 or
TAM, aliquots of 5 × 103 MCF-7 and MDA-MB-231
cells were seeded in triplicate in 96-well plates and trea-
ted with the indicated compounds as described above.
MTT solution was added to the medium to achieve a
final concentration of 1 mg/ml. The cells were incubated
at 37°C and dissolved in 100 μl DMSO after 4 h incubation.
The absorbance of the cell lysates in DMSO solution
was read at 570 nm by a microplate reader (Bio-Rad,
Hercules, CA).
RNA interference
Validated siRNA for ERα and the appropriate control
RNAi (Applied Biosystems) were transfected into MDA-
MB-231 cells using the Silencer siRNA Transfection II
Kit (Applied Biosystems) according to the protocols pro-
vided by the manufacturer. Real-time PCR assay was
performed to verify the result of ERα gene knockout.
Dietary preparation
Two designed diets were used in this study: control diet
(phytoestrogen-free modified AIN-93G diet with 7%
corn oil substituted for 7% soybean oil; TD. 95092;
Harlan Teklad, Madison, WI) and GE diet (modified
AIN-93G diet supplemented with 250 mg/kg genistein;
TD. 00417; Harlan Teklad) [33]. The level of GE in this
diet results in the animals being exposed to concentra-
tions comparable with those received by humans con-
suming high-soy diets [34]. Harland Teklad supplied all
diet ingredients except GE powder obtained from LKT
Laboratories, St. Paul, MN.
Animal models
We have used two mouse models such as the orthoto-
pic breast cancer mouse model (treatment model) and
spontaneous breast cancer mouse model (prevention
model) in this study. Virgin female immunodeficiency
Nu/Nu Nude mice (Crl:NU-Foxn1nu) were used for
xenograft breast cancer study. Nude mice at 4–6 weeks
of age were obtained from Charles River Laboratories
(Wilmington, MA). The C3(1)-SV40 Tag transgenic
mouse model [FVB-Tg(C3-1-TAg)cJeg/JegJ] was used
for prevention model since they can spontaneously de-
velop breast tumors at early ages (around 15–20 wks)
[35]. The C3(1)-SV40 Tag breeder mice at 4 wks were
obtained from Jackson Laboratory (Bar Harbor, ME)
and mice colonies were maintained in our laboratory.
All the mice were housed in the Animal Resource Facil-
ity of the University of Alabama at Birmingham and
were maintained under the following conditions: 12-h
dark/12-h light cycle, 24 ± 2°C temperatures, and 50 ±
10% humidity.
Animal experimental designs
Protocol 1. Tumor xenografts assay for treatment effects
of GE
After one week of acclimatization, Nu/Nu Nude mice
were randomly divided into four groups (5 mice each)
and administered either control or GE diet as described
above. Diets were provided from two weeks prior to in-
jection and the mice continued to receive the corre-
sponding experimental diets throughout the study.
To determine the in vivo efficacy of GE on ERα re-
activation and subsequent chemosensitization to estro-
gen antagonist, TAM, in human ERα-negative breast
tumor xenografts, exponentially growing MDA-MB-231
cells were mixed at a 1:1 ratio with Matrigel (Becton
Dickinson). A 100 μl suspension containing 1 × 106
cells was injected orthotopically into the mammary fat
pad of each mouse.
The experimental groups were as follows: Group
(1). Control group: Mice were fed with control diet as
described previously; Group (2). GE group: Mice were fed
with GE diet (250 mg/kg, equal amount of maximal genis-
tein uptake from daily diet); Group (3). TAM group: Mice
were fed with control diet plus TAM treatment for 3 wks
after two wks of post-injection (25 mg/pellet with 21 days
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release, subcutaneous implantation under the neck area,
Innovative Research of America, Aarasota, FL); Group
(4). GE + TAM group: Mice were fed a GE diet and
received TAM treatment as described above.
Protocol 2. Spontaneous breast cancer mouse model for
preventive effects of GE
The C3(1)-SV40 Tag transgenic mouse model was used
for prevention study of GE treatment because this
mouse model can spontaneously develop breast cancer.
More importantly, this model tends to develop
hormone-independent invasive breast cancer (ERα-nega-
tive breast cancer), which is perfectly suitable to our in-
vestigation purpose for ERα reactivation. The Tag
genotypes were identified at 21 days of life by analysis of
tail DNA using standard PCR techniques according to
previous studies [35]. The C3(1)-SV40 Tag mice at 4–6
weeks of age were randomly divided to different experi-
mental groups (10 mice/group) and control and GE diets
were administered at the indicated time and the diets
were continued throughout the study.
The experimental groups were as follows: Group
(1). Control group: Mice were fed control diet as described
previously; Group (2). GE group: Mice were fed GE diet as
described previously; Group (3). TAM group: Mice were
fed control diet and TAM tablet was implanted subcutane-
ously for 3 wks when tumor size reaches ~400 mm3;
(4). GE + TAM group: Mice were administered with
GE diet and TAM treatment as described above.
Tumor parameters monitoring, experimental endpoint and
tissue sample collection
Tumor diameters and body weight were measured
weekly. Tumor volumes were measured by a caliper and
estimated using the following formula: tumor volume
(cm3) = (length × width2) × 0.523 [31]. For Protocol 1.,
the experiment was finished when the mean of tumor
diameter in the control mice exceeded 1.0 cm following
the guidelines of Institutional Animal Care and Use
Committee at the University of Alabama at Birmingham.
As to Protocol 2., the first palpable tumor was used to
calculate tumor latency for mice that developed either
single or multiple mammary tumors. Mice were sacri-
ficed when the mean of tumor diameter of the biggest
tumor exceeded 1.5 cm and all mice were euthanized
at 25 wks regardless of tumor size. At the end of the
experiment, the mice were sacrificed, primary tumors
were excised and weighed. A tumor slice from each
primary tumor tissue was carefully dissected and fixed
in 10% buffer-neutralized formalin for histology and
immunohistochemistry. Tumor specimens were snap
frozen in liquid nitrogen for further studies such as
RNA and protein extraction. All procedures with ani-
mals were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of
Alabama at Birmingham.
Quantitative real-time PCR
Both ERα-positive MCF-7 and ERα-negative MDA-
MB-231 and MDA-MB-157 cells were cultured and
treated as described above. Total RNA from cells or
mice tumor tissues was extracted using the RNeasy kit
(Qiagen, Valencia, CA) according to the manufac-
turer’s instructions. Genes of interest were amplified
using 1 μg of total RNA reverse transcribed to cDNA
using the Superscript II kit (Invitrogen) with oligo-dT
primer. In the real-time PCR step, PCR reactions were
performed in triplicate and primers specific for ERα,
progesterone receptor (PGR), DNA methyltransferase
(DNMT), histone deacetylase (HDAC) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) provided by
Inventoried Gene Assay Products (Applied Biosystems,
Foster City, CA) were used for Platinum Quantitative
PCR Supermix-UDG (Invitrogen) in a Roche LC480
thermocycler. Thermal cycling was initiated at 94°C for
4 min followed by 35 cycles of PCR (94°C, 15 s; 60°C,
30 s). GAPDH was used as an endogenous control,
and vehicle control was used as a calibrator. The rela-
tive changes of gene expression were calculated using
the following formula: fold change in gene expression,
2-ΔΔCt = 2-{ΔCt (treated samples) - ΔCt (untreated control samples)},
where ΔCt = Ct (test gene) - Ct (GAPDH) and Ct repre-
sents threshold cycle number.
Western blot analysis
For western blot analysis, protein extracts were pre-
pared by RIPA Lysis Buffer (Upstate Biotechnology,
Charlottesville, VA) according to the manufacturer’s
protocol. Proteins (50 μg) were electrophoresed on a 10%
SDS-polyacrylamide gel and transferred onto nitrocellu-
lose membranes. Membranes were probed with anti-
bodies to ERα (Ab-12; NeoMarkers, Fremont, CA),
HDAC1 (H11; Santa Cruz Biotechnology) and DNMT1
(ab 13537; Abcam, San Francisco, CA ) respectively, then
each membrane was stripped with and reprobed with
beta-actin antibody (13E5, Cell Signaling Technology,
Boston, MA) as loading control. Molecular weight mar-
kers were run on each gel to confirm the molecular size
of the immunoreactive proteins. Immunoreactive bands
were visualized using the enhanced chemiluminescence
detection system (Santa Cruz Biotechnology) following
the protocol of the manufacturer.
Immunohistochemical determination of tumor cell
proliferation and ERα expression
Tumor sections (5 μm thick) were deparaffinized and
rehydrated in a series of graded alcohols. Following re-
hydration, an antigen retrieval process was performed by
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placing the slides in 10 mmol/L sodium citrate buffer
(pH 6.0) at 95°C for 20 min followed by 20-min cooling
at room temperature. The sections were washed in PBS
and nonspecific binding sites were blocked with 1% bo-
vine serum albumin with 2% goat serum in PBS before
incubating with either anti-proliferating cell nuclear
antigen (PCNA) (Cell Signaling Technology) or anti-ERα
antibody for 2 h at room temperature. After washing
with PBS, the sections were incubated with biotinylated
secondary antibody for 45 min followed by horseradish
peroxidase-conjugated streptavidin, washed in PBS, incu-
bated with diaminobenzidine substrate, and counterstained
with hematoxylin. Photographs of representative pictures
were taken and the numbers of PCNA-positive or ERα-
positive cells were detected and counted using a light
microscope. The results are presented as the number of
positive cells × 100 divided by the total number of cells.
Chromatin Immunoprecipitation (ChIP) Assay
MDA-MB-231 cells were treated with 25 μM GE and
100 μg/ml TSA alone or in combination for the indicated
times. Approximately 2 × 106 cells were cross-linked with
a 1% final concentration of formaldehyde (37%, Fisher
Chemicals, Fairlawn, NJ) for 10 min at 37°C. ChIP assays
were performed with the EZ Chromatin Immunoprecipita-
tion (EZ ChIPTM) assay kit according to the manufacturer’s
protocol (Upstate Biotechnology) as described previously
[29,32]. The epigenetic antibodies used in the ChIP assays
were ChIP-validated acetyl-histone H3 (Upstate Biotech-
nology), acetyl-histone H3-Lys9 (H3K9) (Upstate Bio-
technology), acetyl-histone H4 (Upstate Biotechnology),
dimethyl-histone H3-Lys4 (H3K4) (Upstate Biotechnol-
ogy), histone deacetylase1 (HDAC1) (Santa Cruz Bio-
technology) and DNMT1 (Abcam, Cambridge, MA).
ChIP-purified DNA was amplified by standard PCR
using primers specific for the ERα promoter ranging
from +78 to +227 in exon 1 and yielding a 150 bp frag-
ment: sense, 5’-GAACCGTCCGCAGCTCAAGATC-3’
and anti-sense, 5’- GTCTGACCGTAGACCTGCGCGT
TG -3’. PCR amplification was performed using the
2×PCR Master Mix (Promega, Madison, WI) and the reac-
tion was initiated at 94°C for 4 min followed by 30 cycles
of PCR (94°C, 30 s; 56°C, 30 s; 72°C, 1 min), and
extended at 72°C for 5 min. After amplification, PCR
products were separated on 1.5% agarose gels and
visualized by ethidium bromide fluorescence using
Kodak 1D 3.6.1 image software (Eastman Kodak Com-
pany, Rochester, NY). Quantitative data were analyzed
using the Sequence Detection System software version
2.1 (PE Applied Biosystems, Foster City, CA).
HDACs and DNMTs activity assay
Nuclear protein from cultured MDA-MB-231 cells and
breast tumor tissues was extracted by using the nuclear
extraction reagent (Pierce, Rockford, IL). The activities
of HDACs (Active Motif, Carlsbad, CA) and DNMTs
(Epigentek, Brooklyn, NY, USA) were performed according
to the manufacturer’s protocols as reported previously
[32,36]. The enzymatic activities of HDACs and DNMTs
were detected by using a microplate reader at 450 nm.
Statistical analyses
Microscopic immunohistochemical analysis of tissue
sections was performed using an Olympus BX41 micro-
scope fitted with a Q-color 5 Olympus camera. Results
from Real-time PCR and ChIP assays were derived from
at least three independent experiments. For quantifica-
tion of ChIP products, Kodak 1D 3.6.1 image software
was used. The protein levels were quantified by optical
densitometry using ImageJ Software version 1.36b
(http://rsb.info.nih.gov/ij/). Statistical significance be-
tween treatment and control groups was evaluated by
one-way ANOVA followed by Tukey’s test for multiple
comparisons by using GraphPad Prism version 5.00 for
Windows, GraphPad Software (www.graphpad.com).
Tumor-free intervals (tumor latency) for survival curves
were calculated using the Mantel-Cox proportional model
and differences were tested using the log-rank statistic.
Values were presented as mean ± SD and P < 0.05 was
considered significant.
Results
Combination treatment with GE and TSA synergistically
reactivated ERα expression in ERα-negative breast
cancer cells
Our previous studies have shown that (−)-epigallocate-
chin-3-gallate, an active component in green tea poly-
phenols, can induce ERα re-expression in ERα-negative
breast cancer cells [32]. We hypothesize that dietary GE
may have a similar effect on ERα expression since both
compounds are considered to exert their anticancer
properties via epigenetic control. We initiated our study
to determine whether GE can impact ERα expression
and the optimal dose and time point that will induce
ERα activation. We treated ERα-negative breast cancer
cells, MDA-MB-231, with various concentrations of GE
at different time points and observed ERα transcription
under these treatments. As shown in Figure 1A, a sig-
nificant increase of ERα transcription (p<0.001) was
observed with 25 μM of GE and the ERα reactivation
was predominant at 3 days of treatment. This GE con-
centration is considered to be equivalent to the maximal
consumption of soybean product per day or a pharma-
ceutically available GE supplementary tablet, suggesting
a potential bioavailability of this treatment. This result
indicates that treatment with 25 μM GE at 3 days could
serve as an optimal condition in regulating ERα re-
expression in ERα-negative breast cancer cells.
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We also tested combination effects of GE with
other epigenetic modulators such as the histone dea-
cetylase (HDAC) inhibitor, trichostatin A (TSA), and
a demethylation agent, 5-aza-2’-deoxycytidine (5-aza),
on ERα re-expression because epigenetic mechanisms
such as histone modifications and DNA methylation
were known to contribute to ERα regulation. Both
TSA and 5-aza have been reported to successfully acti-
vate ERα transcription in human ERα-negative breast
cancer cells [13], but have not previously been com-
bined with GE in ER studies. Consistent with previous
studies, our results indicated that 5-aza and TSA alone
reactivated ERα expression in MDA-MB-231 cells.
More importantly, we found that the combined treat-
ment of GE and TSA induced a significant synergistic
effect on ERα re-expression, much more so than GE in
combination with 5-aza (Figure 1B). This effect was
further confirmed by the results of ERα protein levels
in Figure 1E showing that combination treatment using
GE and TSA led to more abundant ERα re-expression
than the other treatments administered alone.
To further verify the GE effects on ERα reactivation
on an ERα-negative breast cancer cell line other than
MDA-MB-231 cells, we performed similar experiments
on ERα-negative MDA-MB-157 cells (Additional files
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Figure 1 GE and TSA synergistically induced ERα re-expression in ERα-negative MDA-MB-231 breast cancer cells. A) Graphic presentation
of dose- and time- dependent ERα expression by GE treatment. MDA-MB-231 cells were plated in 6-well plates in triplicate and exposed to
various concentrations of GE for up to 3 days. B) ERα expression changes by the combined treatment of GE with 5-aza (left) and TSA (right). The
MDA-MB-231 cells were treated with or without either 25 μM GE or 2 μM 5-aza and 100 ng/ml TSA alone or together for 3 days. Control cells
were grown in parallel with the treated cells but received vehicle DMSO. Quantitative real-time PCR was performed to measure relative
transcription of ERα. C) Cellular viability in response to E2 and tamoxifen (TAM). D) The expression of PGR, an ERα target gene, in response to E2
and tamoxifen. GE and/or TSA-pretreated MDA-MB-231 cells were treated with or without 10 nM of E2 or 1 μM TAM for 1 days. MCF-7 cells
served as a positive control. Cells were harvested at the indicated time periods and assessed for cellular viability and PGR expression, respectively.
Cellular viability was measured by MTT assay and PGR expression was detected by quantitative real-time PCR. Data are in triplicate from three
independent experiments and were normalized to GAPDH and calibrated to levels in the relevant control samples. Bars, SD; *, P < 0.05, * * P < 0.001,
significantly different from control; £, P < 0.05, significantly different from GE (Figure 1B); †, P < 0.05, significantly different from 5-aza or TSA
(Figure 1B). E) The ERα protein levels were determined by western-blot analysis. MCF-7 cells served as a positive control. GAPDH antibody was
used to ensure equal loading. Representative photograph from an experiment was repeated three times.
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up-regulation in response to GE treatment and combin-
ation treatment of 25 μM of GE with TSA but not 5-aza
resulted in a synergistic effect on ERα reactivation. This
similar response to GE treatment as seen in MDA-MB-
231 cells suggests that this combination regimen results
in a prevalent effect on ERα reactivation in different
ERα-negative breast cancer cells as well. In Additional
file 1C, we also evaluated the potential toxicity of this
novel combination in normal human mammary epithe-
lial cells (HMECs) and found that neither of these two
compounds acting alone nor in combination caused in-
hibitory effects on cell viability in HMECs cells indicat-
ing the combined treatment of GE and TSA is
potentially safe and may apply for in vivo studies.
Our results reveal a novel combination regimen by
using a bioactive compound, GE, and an HDAC inhibi-
tor, TSA, in converting ERα status which may provide a
promising therapeutic strategy especially in ERα-nega-
tive breast cancer. These results also indicate a more im-
portant role of histone modification rather than DNA
methylation in GE induced-ERα reactivation.
GE and TSA re-sensitized ERα-negative breast cancer cells
to E2 and TAM
In the presence of ER, a series of ER-dependent cellular
responsiveness is stimulated including cellular prolifera-
tion and downstream ER-response gene expression by
binding ER with hormone signals such as 17β-estradiol
(E2) [4,5]. This effect could be blocked by the E2 antag-
onist, tamoxifen (TAM), leading to cell growth arrest by
competing with E2 binding to ER [8]. Since our afore-
mentioned findings suggested that GE combined with
TSA led to synergistic re-expression of ERα mRNA in
ERα-negative breast cancer cells, we therefore sought to
investigate whether this re-expression of ERα could ef-
fectively respond to E2 and TAM treatments. We inves-
tigated the changes in cellular viability as well as the
expression of the ERα-responsive downstream gene, pro-
gesterone receptor (PGR), in response to E2 or TAM,
with treatments of GE and TSA alone or together in
ERα-negative MDA-MB-231 breast cancer cells. ERα-
positive MCF-7 breast cancer cells served as a positive
control. As shown in Figures 1C and 1D, MCF-7 cells
showed a significant response to E2 and TAM, whereas
untreated MDA-MB-231 cells have no response to these
two compounds with respect to cell growth and PGR ex-
pression. Treatments with either GE or TSA alone
induced a partial response to E2 and TAM. In particular,
GE treatment alone led to a positive response in cell
growth but not in PGR expression, whereas TSA acting
alone caused PGR response but not in cell growth in re-
sponse to E2 and TAM, which is likely due to the limited
increased level of ERα re-expression with treatment of
GE and TSA alone. Eventually, combined treatments
with GE and TSA resulted in significant changes in cellu-
lar growth and downstream PGR expression in response
to E2 and TAM in ERα-negative MDA-MB-231 cells in a
similar manner to that observed in ERα-positive MCF-7
cells (Figures 1C and 1D).
We also performed RNAi experiments to further test
whether ERα presence plays an important role in GE
and/or TAM-induced cellular growth inhibition in ERα-
negative MDA-MB-231 breast cancer cells. As shown in
Additional file 2A and 2B, GE alone or with TAM treat-
ment resulted in a significant inhibition of cellular via-
bility compared to these two treatments with silencing
expression of ERα. These results suggest that reactivated
ERα potentiates the efficacy of GE and TAM against
ERα-negative breast cancer cells.
Our results indicate that the combination of GE and
TSA can induce functional ERα re-activation and re-
sensitize ERα-negative breast cancer cells to E2 activator
and TAM antagonist. This novel combination could
provide an important clinical implication in future al-
ternative therapeutic strategies for hormone-resistant
breast cancer.
GE and TSA led to histone modification changes in the
ERα promoter
GE has been reported to influence gene expression via
epigenetic mechanisms and ERα expression is frequently
mediated by epigenetic controls. Therefore, we focused
on our subsequent experiments to investigate whether
GE may affect histone remodeling on the ERα gene. We
tested several chromatin markers, for example, acetyl-
H3, acetyl-H3K9, acetyl-H4 and dimethyl-H3K4, to ex-
plore enrichment changes of these markers that may
affect ERα gene expression in response to GE in MDA-
MB-231 cells. We found that GE treatment can increase
enrichment of three histone acetylation chromatin mar-
kers, acetyl-H3, acetyl-H3K9, acetyl-H4 (especially in the
histone H3 molecule, P < 0.05), and slightly increased
one histone methylation chromatin marker, dimethyl-
H3K4 (Figures 2A and 2B). The abundance of these
chromatin markers indicates a loosening chromatin
structure leading to active gene transcription. In
addition, histone remodeling changes were more prom-
inent when GE was combined with TSA than either
treatment alone, which is consistent with our aforemen-
tioned findings. Our results indicate that GE and TSA
treatment results in a strengthened ERα expression that
might be due to enhanced histone remodeling of the
ERα gene induced by this combination.
Epigenetic enzymes changes in response to GE
To further interpret the mechanisms of epigenetic
modulations on GE-induced ERα re-expression in ERα-
negative breast cancer cells, we assessed two important
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epigenetic enzymatic activities such as HDACs and
DNMTs. As shown in Figure 2C, both GE and TSA alone
can significantly reduce HDACs activity, while their com-
bination led to a more prominent reduction than any
compound acting alone. As to DNMTs activity shown in
Figure 2D, only GE treatment caused a significant inhib-
ition suggesting that GE and TSA-induced ERα reactiva-
tion may be primarily mediated through histone
remodeling rather than DNA methylation. We also found
that GE caused a reduction of binding to the ERα pro-
moter as well as gene expression for both HDACs and
DNMTs (Figures 2E and 2F). The different DNMTs en-
zymatic activities and protein expression in response to
GE and/or TSA treatment suggest that DNMT1 may
affect ERα expression through transcription regulation
rather than directly influencing DNA methylation status
in the ERα promoter, which has been confirmed by fur-
ther bisulfite sequencing analysis on the ERα promoter
(data not shown). Although GE alone and combination
treatment also inhibited DNMTs binding and its expres-
sion, it might lead to DNMT-involved transcriptional re-























































































































Control        GE           TSA       GE+TSA
Figure 2 Epigenetic alterations in response to GE and/or TSA treatments. (A) Histone modification patterns in the ERα promoter were
analyzed by ChIP assay. Representative photograph from an experiment was repeated in triplicate. (B) Histone modification enrichment in the
ERα promoter was calculated from the corresponding DNA fragments amplified by ChIP-PCR as shown above. MDA-MB- 231 cells were treated as
described previously and analyzed by ChIP assays using chromatin markers including acetyl-H3, acetyl-H3K9, acetyl-H4, dimethyl-H3K4 and mouse
IgG control in the promoter region of ERα. Inputs came from the total DNA and served as the same ChIP-PCR conditions. DNA enrichment was
calculated as the ratio of each bound sample divided by the input while the untreated MDA-MB-231 control sample is represented as 1. (C) HDACs
enzymatic activity. (D) DNMTs enzymatic activity. Nuclear proteins of MDA-MB-231 cells were extracted after the treatment as described above. The
HDACs and DNMTs activity assays were performed according to the manufacturer’s protocols. (E) Binding abilities of HDACs and DNMTs in the ERα
promoter were determined by ChIP assay as described previously. The values of enzymatic activities of HDACs and DNMTs are the means of three
independent experiments. Columns, mean; Bars, SD. *, P < 0.05, significantly different from control; £, P < 0.05, significantly different from GE; †,
P < 0.05, significantly different from TSA. (F) The protein level changes of HDACs and DNMTs were determined by western-blot analysis.
GAPDH antibody was used to ensure equal loading. Representative photograph from an experiment was repeated three times.
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ERα re-expression [37]. These results indicate that GE
alone affects ERα expression most likely via both epi-
genetic pathways involving histone modification and
DNA methylation, whereas, when GE is combined with
TSA, a synergistic effect of ERα reactivation is induced
by a more efficient epigenetic response to histone
modification rather than DNA methylation. Taken to-
gether, our results further indicate that GE can restore
ERα expression in ERα-negative breast cancer cells
through influencing epigenetic mechanisms and this ef-
fect is strengthened in the presence of TSA, a deacety-
lation inhibitor.
Dietary GE inhibited the growth of breast cancer and
increased therapeutic sensitivity of TAM in ERα(−) breast
cancer xenografts
As we have found that GE treatment led to function-
ally ERα reactivation in ERα-negative breast cancer
cells in vitro, we sought to determine whether dietary
administration of GE can inhibit the growth of ER(−)
breast cancer through combining with anti-hormone
therapy such as TAM in vivo. ERα-negative breast can-
cer cells, MDA-MB-231, were used to grow xenografts
in athymic nude mice that had been fed a diet supple-
mented with GE for two weeks before injection of the
tumor cells and continued throughout the study. We
have not found any differences in the daily consump-
tion of diet and drinking water by the mice among the
different groups and the mice that were given the GE
diet (250 mg/kg) did not exhibit any physical sign of
toxicity (data not shown). Previous studies also have
shown that administration of GE in the diet at this
concentration is equivalent to the maximal consump-
tion of soybean products [34]. Asian women who con-
sume soybean food as their primary daily diet show
low incidence of breast cancer suggesting protective
effects of this diet [18,19,38]. Periodic measurement of
the tumor volume indicated that the average tumor
growth in terms of total tumor volume per mouse in
the control group was dramatically increased compared
with the GE-treated group (Figure 3A). In addition, in
the group of mice that received the GE diet, the over-
all tumor growth rate was inhibited and the tumor
volume at the termination of the experiment was signifi-
cantly reduced as compared with the non-GE treated
control group (p < 0.001). The mice were sacrificed on
the 28th day after tumor cell implantation and the
tumors were harvested, and the wet weight of the tumor
per mouse in each treatment group was recorded. As
shown in Figure 3B, the wet weight of the xenograft
tumor per mouse was significantly lower in the mice
administered GE diet than in the mice fed control diet.
This result indicates that dietary GE can inhibit ERα-
negative breast cancer in vivo.
The second in vivo tumor xenograft protocol was
designed to evaluate the therapeutic effect of dietary GE
and anti-estrogen agent, TAM, on ERα-negative breast
cancer based on our previous finding indicating that GE
can restore ERα reactivation in ERα-negative breast can-
cer cells. GE diet was given as described previously and
TAM was administered two weeks post-injection and
maintained release for up to three weeks. As expected,
we did not observe any regression in the size of the
established tumors after TAM was administered alone
due to its poor effect on ERα-negative breast cancer. In
the GE-fed mice group, TAM treatment resulted in a
significant inhibition of tumor growth rate (p <0.001)
(Figure 3C). This inhibitory effect on tumor volume
began to appear only one week after TAM was admini-
strated and continued until the experiment was termi-
nated. The tumor weight graph in Figure 3D showed the
same pattern. To further evaluate the preventive or
therapeutic effect of the GE diet alone or combined with
TAM treatment on ERα-negative breast xenografts, the
inhibition rate on tumor growth (IR) was introduced to
compare the efficacy of these treatments. As shown in
Table 1, IR in the GE group was significant increased to
50.89% as compared with the non-treatment control
(0%) and TAM alone (−1), whereas, most strikingly, IR
in the GE plus TAM group was further elevated to
96.6% which meant that most of ERα-negative breast
xenografts were inhibited by this novel combination.
This result suggests that dietary GE enhances the anti-
tumor properties of TAM by re-sensitizing ERα-negative
breast cancer to anti-hormone therapy. This finding may
provide a new avenue for alternative therapy by combin-
ation of dietary GE and anti-hormone therapy for refrac-
tory ERα-negative breast cancer.
Dietary GE increased tumor latency and prevented breast
cancer development in spontaneous breast cancer mouse
model
To further evaluate the prevention effect of GE treatment
as well as its impact on subsequent TAM therapy on
ERα-negative breast cancer, we have introduced a spon-
taneous breast cancer model, C3(1)-SV40 Tag transgenic
mouse, in our study. As shown in Figure 3E, GE diet sig-
nificantly increased mean tumor latency (p < 0.001) and
reduced 55.56% of breast tumor incidence by 20 wks of
age since almost 100% of C3(1)-SV40 Tag mice develop
spontaneous breast tumors before 20 wks.
We next sought to study whether mice could respond
to TAM treatment to determine the potential interac-
tions between early dietary GE treatment and tumor re-
sensitizing to anti-hormone therapy when ERα-negative
breast tumor was initiated. We observed tumor growth
by measuring tumor volumes in four treatment groups
up to 6 weeks when tumor size reached limitation of
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Table 1 Tumor suppression effect of GE and/or TAM on mouse tumor xenografts
Animal group Diet and treatment BWCa (g, mean ± SD) TVb (mm3 mean ± SD) RTVc (mean) IRd (%)
Control Modified AIN-93G diet 7% of corn oil instead
of soy oil; no treatment
4.5 ± 1.64 1236.2 ± 195 14.54 -
TAM Diet is control diet; TAM tablet (25 mg/pellet) was
implanted subcutaneously two weeks post-injection
4.9 ± 1.52 1160.5 ± 225.57 14.69 −1
GE GE diet contains 250 mg genistein/kg of modified
AIN-93G diet; no treatment
4.18 ± 1.21 306.9 ± 30.16 7.14 50.89
GE + TAM Diet is GE diet; TAM tablet (25mg/pellet) was implanted
subcutaneously two weeks post-injection
4.38 ± 1.46 24.33 ± 4.04 0.45 96.9
a. Body weight change (BWC) = (BW on sacrificing day)-(BW of experiment initiation); b. Tumor volume (TV) = (length × width2) × 0.532; c. Relative Tumor volume
(RTV) = (TV on sacrificing day)/(TV on day 1 of injection); d. Inhibition rate on tumor growth (IR) = {1 - (mean RTV of the treatment group)/(mean RTV of the












































































































































Figure 3 Breast tumor growth in mouse models by dietary GE and/or TAM treatments. Two mouse models were used in this study. Figures 3A,
3B, 3C and 3D are involved in orthotopic breast cancer mouse model (Protocol 1, seen in Materials and methods). Female athymic nude mice were
injected with MDA-MB-231 cells. GE or control diets were provided from two weeks prior to injection and one 21-day release of 25 mg TAM pellet was
implanted subcutaneously two wks post-injection. A) and B) GE alone inhibited the growth of mice xenografts. C) and D) GE re-sensitized TAM in tumor
suppression. A) and C) Tumor volume during the experiment. B) and D) tumor xenograft tissues were harvested at the termination of the
experiment. Figures 3E and 3F are spontaneous breast cancer mouse model (Protocol 2). Diets were administered to C3(1)-SV40 Tag transgenic mice
at 4–6 wks of age and TAM treatments were performed when tumor volumes reaches to ~400 mm3. E) Dietary GE increased the latency of tumor
development. F) Tumor volume changes after TAM implantation. Tumor volumes were calculated by using the formula: volume (mm3) = (length ×
width2) × 0.523, and represented as mean ± SD (mm3) for each group. Tumor weight is the wet weight of the tumor per mouse in each group
and is reported as mean ± SD (g). The actual tumor images were selected to represent the difference of tumor sizes and a ruler was included for
tumor measurement. Symbols and columns, mean; Bars, SD from 5 or 10 mice per group; * p < 0.01, **, p < 0.001 significantly different from
control group; †, P < 0.05, significantly different from TAM group (Figure 3F); £, P < 0.05, significantly different from GE (Figure 3F).
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maximal growth. As shown in Figure 3F, spontaneous
tumor growth was only slightly inhibited after TAM
treatment, but was significantly reduced by GE treat-
ment. Moreover, GE-fed mice exhibited excellent re-
sponse to TAM treatment and tumor growth rate was
dramatically reduced compared to the other three
groups after three-weeks TAM treatment (Figure 3F).
These data not only suggest a prevention effect of diet-
ary GE on ERα-negative breast cancer development, but
more importantly, long-term consumption of GE-rich
food such as soybean products may reinforce efficacy of
TAM treatment for ERα-negative breast cancer.
Dietary GE inhibited tumor cell proliferation and
increased ERα expression
Uncontrolled cell proliferation is one of the most im-
portant characteristic features of cancer, including
breast cancer. We therefore analyzed in vivo breast
cancer tumors for the potential anti-proliferative
property of GE administration. For this purpose,
tumor samples were collected and used from the ex-
periment of Figure 3 and subjected to immunohisto-
chemical evaluation. Immunohistochemical detection
of PCNA-positive cells in mice xenograft tumors
(Protocol 1, see Materials and methods) indicated that
the percentages of proliferating cells were significantly
lower in GE alone and combined with TAM-treated
mice tumors than the tumors from the control mice
and TAM alone, respectively (Figures 4A and 4B, left
panel). Moreover, positive-proliferated cells in the
tumor tissue from the combination treatment of GE
and TAM were further reduced compared with GE
acting alone. In the breast tumors from the mouse
prevention model (Protocol 2), we found a similar
trend as seen in the mouse xenograft tumors
(Figures 4C and 4D, left panel) suggesting that GE
can prevent breast tumorigenesis via inhibiting tumor
cell proliferation and further consolidate anti-tumor
effect of TAM treatment. These observations reveal
strong preventive and therapeutic efficacy of GE
against in vivo ERα-negative breast tumor growth and
this effect is further enhanced by combination treat-
ment with TAM.
Since the aforementioned studies indicated that GE
treatment induced functional ERα reactivation in vitro,
we sought to further investigate whether dietary GE can
impact ERα expression that may lead to TAM re-
sensitizing to ERα-negative breast cancer in vivo. We
evaluated ERα expression in mice tumor samples using
immunohistochemical analysis. As shown in Figures 4A
and 4B, right panel, expression of ERα-positive cells was
increased in the xenograft tumor samples from both the
ERα






















































































































Figure 4 GE and TAM inhibited the expression of PCNA and increased ERα expression in vivo. Immunohistochemical analysis was
performed in tumor samples to detect PCNA-positive cells for proliferation index (left panel) and ERα in vivo expression (right panel). A) and B)
PCNA and ERα expression in MDA-MB-231 tumor xenogratfs (Protocol 1). C) and D) PCNA and ERα expression in C3(1)-SV40 Tag transgenic mice
tumors (Protocol 2). Immunohistochemical data in terms of percentage of positive cells are presented as mean ± SD from each group. PCNA-
positive and ERα-positive cells were counted in 5 different areas of the sections, and data are summarized in terms of percent positive cells from
all tumor samples. Representative photograph from one field of each experimental group. Columns, mean; Bars, SD from 5 or 10 mice per group;
*, p < 0.05 significantly different from control group. †, P < 0.05, significantly different from TAM alone group.
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GE-fed (5.41%) and GE + TAM-fed groups (8.21%) com-
pared with that of in the control (3.92%) and TAM-fed
groups (3.81%), respectively. Furthermore, this effect was
more prominent in the mouse prevention model
(Figures 4C and 4D, right panel), indicating that long-
term consumption of GE diet may lead to a better
impact on ERα reactivation and TAM treatment en-
hance this effect. We also found that GE treatment
alone can induce a significant increment of ERα ex-
pression regardless of additional TAM treatment
(Figure 4 and Additional file 2C), indicating other
potential regulatory mechanisms besides the ER path-
way may be involved in GE and TAM-enhanced
tumor inhibition on ERα-negative breast cancer.
Taken together, these findings are consistent with our
previous studies indicating GE results in increased ex-
pression of ERα both in vitro and in vivo, which
enhances the efficacy of TAM against ERα-negative
breast cancer.
Expression changes of epigenetic enzymes may affect
ERα reactivation in vivo
As we have observed that epigenetic factors may play an
important role in regulating GE-induced ERα re-
expression in ERα-negative breast cells, we next sought
to determine whether GE modulated ERα expression via
epigenetic mechanisms in vivo. We therefore chose to
evaluate the expression status of DNMT1 and HDAC1
as the most important epigenetic enzymes involving
DNA methylation and histone modification accompan-
ied with expression changes of ERα. Gene expression
status at the protein and mRNA levels in both xenograft
and spontaneous breast tumors were detected by
western-blot assays and real-time PCR.
As indicated in Figure 5A left panel, first row and
Figure 5B left panel, GE treatment alone and combin-
ation treatment of GE and TAM induced significant ERα
protein re-expression in mice breast xenografts (p <0.001).
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Figure 5 Protein expression changes of ERα and two epigenetic modulators, HDAC1 and DNMT1 in mice breast tumors. Left panel,
MDA-MB-231 breast tumor xenografts (Protocol 1); right panel, C3(1)-SV40 Tag transgenic mouse tumors (Protocol 2). A) Protein levels of ERα,
DNMT1 and HDAC1 in breast tumors using western blot analysis. GE and/or TAM treatments were described in Materials and methods.
Representative blots are presented from the independent experiments from all tumors per group with identical results. All the analyses in tumor
samples were performed at the termination of the experiment. B) Histogram of quantification of the protein levels. Data are in triplicate from
three independent experiments and were normalized to actin and calibrated to levels in control samples. Columns, mean; Bars, SD; *, P < 0.01, * *
P < 0.001, significantly different from control.
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significantly increased in GE-fed alone/combination mice
xenografts compared with control group (p <0.05), espe-
cially in the presence of GE (p <0.01). Although the mRNA
level of ERα treated by TAM alone in mouse xenografts
showed significant increased expression in Figure 6A left
panel, the protein level did not show similar change as
indicated in Figure 4B and Figure 5B left panel. In addition,
our in vitro result (Additional file 2C) and results in spon-
taneous mouse models (Figure 4D and Figure 5B right
panel) did not show similar effects, which indicates that
TAM treatment alone may not be able to induce ERα ex-
pression and this solo increment of ERα may involve cer-
tain post-translational regulation depending on different
model system or cell types. ERα protein expression was
significantly increased in the spontaneous breast tumors
with GE treatment alone or combined GE and TAM treat-
ment as compared to the control group (Figure 5A right
panel, first row and Figure 5B right panel), which is con-
sistent with its expression at the mRNA level (Figure 6A
right panel).
In terms of the expression status of DNMT1 and
HDAC1 (Figures 5, 6B and 6C), dietary GE caused a
gradual reduction of the expression of these enzymes at
the protein and mRNA levels in both tested mouse mod-
els, especially when GE and TAM were acting together
(p <0.01). These results indicate that epigenetic mechan-
isms may contribute to GE-induced ERα re-activation
leading to increased sensitivity of TAM therapy toward
intractable ERα-negative breast cancer.
Epigenetic enzymatic activities changes in response to GE
and TAM treatment in vivo
Our observations on expression changes of DNMT1 and
HDAC1 indicated that GE alone or combined with TAM
treatment led to a significant decrease in expression of
these two important epigenetic enzymes (Figures 5, 6B
and 6C). We next sought to investigate whether this
reduced expression can result in direct enzymatic activ-
ities changes in vivo that may contribute to epigenetic
mechanisms-modulated gene expression alteration such
as ERα re-activation. We assessed the epigenetic enzym-
atic activities of HDACs and DNMTs in both xenograft
and spontaneous breast tumors. As shown in Figure 7A,
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Figure 6 mRNA expression changes of ERα, HDAC1 and DNMT1 in mice breast tumors. Left panel, MDA-MB-231 breast tumor xenografts
(Protocol 1); right panel, C3(1)-SV40 Tag transgenic mouse tumors (Protocol 2). A) mRNA expression of ERα. B) mRNA expression of DNMT1. C)
mRNA expression of HDAC1. mRNA expression in breast tumors was analyzed by quantitative real-time PCR. GE and/or TAM treatment were
described in Materials and methods. All the analyses in tumor samples were performed at the termination of the experiment. Columns, mean;
Bars, SD; *, P < 0.05, significantly different from control; * * P< 0.01, significantly different from control.
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can significantly reduce HDACs activity compared to the
control group in the two tested mouse models. In
addition, we found that the combination of GE and
TAM led to a more prominent reduction than any treat-
ment acting alone in mouse xenografts rather than spon-
taneous breast tumors, suggesting that GE exposure
time could be a key factor influencing TAM-induced
epigenetic regulation. However, as to DNMTs activity
shown in Figure 7B, only GE treatment caused a slight
inhibition suggesting that dietary GE treatment is pri-
marily mediated through histone remodeling rather than
DNA methylation, which is consistent with our previous
in vitro studies. We found that TAM, acting as an anti-
hormone drug, may exert its anti-cancer properties by
interacting with epigenetic modulators such as DNMTs
or HDACs [39]. This may explain our previous results
indicating that TAM enhanced GE-induced anti-cancer
properties through, at least in part, ERα reactivation.
TAM may influence epigenetic pathways that facilitate
the epigenetic effects of GE leading to ERα activation.
These results suggest an important synergistic inter-
action between GE and TAM against ERα-negative
breast cancer.
In summary, our results indicate that dietary GE may
affect ERα expression via modulating epigenetic pathways,
especially, histone modification. In addition, dietary GE
reinforced TAM-caused anti-cancer effects through
increased therapeutic target via up-regulated ERα and po-
tential interaction between these two compounds resulting
in epigenetic modulations of more relevant genes.
Discussion
Human breast cancer is phenotypically heterogeneous
and the clinical treatment principle of this disease is
largely dependent on distinct molecular alterations, for
example, the expression status of the nuclear estrogen
receptor (ER) [1-3]. ER-positive breast cancers respond
to hormonal therapy; however, at least 20% of breast
cancer cells that lack of ER expression are more aggres-
sive and have a poor prognosis [3]. Previous work from
our laboratory and others has highlighted the restoration
of ER signaling through epigenetic pathways for applica-
tion to a new therapeutic strategy for the ER-negative
breast tumors that do not respond to hormone receptor-
based treatment such as tamoxifen (TAM) [32].
We started our work on an epigenetic diet, soybean
genistein (GE), not only because its proven anti-cancer
properties, but also its excellent physiological availability
and safety use potentially for clinical transition. It is a
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Figure 7 Epigenetic enzymatic activities in response to dietary GE and/or TAM treatment in mice breast tumors. Left panel, MDA-MB-
231 breast tumor xenografts (Protocol 1); right panel, C3(1)-SV40 Tag transgenic mouse tumors (Protocol 2). GE and/or TAM treatment were
described above. A) HDACs enzymatic activity. B) DNMTs enzymatic activity. Nuclear proteins from mice breast tumors were extracted as
described previously. The HDACs and DNMTs activity assays were performed according to the manufacturer’s protocols. The values of enzymatic
activities of HDACs and DNMTs are the means of three independent experiments from all tumors per group. Columns, mean; Bars, SD. *, P < 0.05,
significantly different from control; * * P< 0.01, significantly different from control.
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classes of breast cancers if ER expression is elevated and
anti-hormone treatment will be available for the refrac-
tory ERα-negative breast cancer. Strikingly, our results
showed that GE induced a maximal ERα increment at
25 μM in a time-dependent manner (Figure 1A). The
concentration of 25 μM GE is equivalent to a maximal
daily consumption of soybean product and can also be
physiologically attained in blood serum when admini-
strated with a pharmaceutically-available genistein tablet
[40], which suggests that this concentration has good
bioavailability that could potentially apply for in vivo
studies. Our further studies revealed a synergistic effect
of GE treatment combined with an epigenetic modulator,
the HDAC inhibitor TSA, suggesting that this combin-
ation may trigger a reciprocal relationship and histone
regulations are likely to contribute to favorably stimulate
ERα expression. Active ERα signaling transports hor-
mone estrogen signal from the outside space of the cell
membrane into the nucleus to regulate cellular prolifera-
tion and differentiation in normal mammary glands as
well as the malignant progression of breast cancer [4,5].
Our further observation of a positive response to hormone
signal E2 and E2 antagonist, TAM, suggests a functional
ERα re-expression and restoration of ERα signal transduc-
tion in GE-treated ERα-negative breast cancer cells. These
findings should have practical importance since endocrine
therapies are usually designed to block ER function, and
GE may be applied for sensitization of ERα-negative breast
cancer cells to anti-hormone therapy.
The bioactive dietary component, for instance, green
tea EGCG {(−)-epigallocatechin-3-gallate}, has been
shown to activate ER expression via epigenetic control
in vitro [32,41]. We speculated that GE may impact ER
gene expression through similar epigenetic regulations
as EGCG. Our studies revealed that histone modification
may play a more important role in regulating GE-
modulated ERα restoration rather than DNA methyla-
tion. Histone modifications affect the basic structure of
the chromatin unit, the nucleosome, and histone acetyl-
ation or deacetylation changes are considered to be the
most prevalent mechanisms of histone modifications
[42]. Histone acetylation results in an open chromatin
structure leading to active gene transcription. We found
that treatment with GE, especially GE combined with
TSA, increased the histone acetylation level in the ERα
promoter region, which could be considered as an im-
portant contributor for ERα reactivation. Although we
did not find any methylation status changes in the ERα
promoter region by GE treatment, ERα can be regulated
by numerous cis-regulatory elements located upstream
of the coding sequence of ERα and DNA methylation
may influence these elements leading to ERα expression
change. In addition, altered DNMTs enzymatic activities
and protein expression in vitro and in vivo in response
to GE treatment indicate that DNA methylation may
affect ERα expression through DNMT-involved tran-
scription regulation, suggesting DNA methylation may
also play a role in GE-induced ERα activation.
We further tested this hypothesis by using two differ-
ent mouse models, the orthotopic and spontaneous
breast tumor mouse models, aiming at treatment and
preventive effect of dietary GE, respectively. We initiated
our in vivo studies by applying single GE treatments ra-
ther than GE/TSA combination in mice diet due to po-
tential toxicity of TSA in previous clinical studies
[43,44]. Our in vivo mouse studies supported our
in vitro results suggesting that dietary GE can not only
prevent ERα-negative breast cancer development, but
also greatly enhance the anti-cancer capacity of TAM
treatment. Although GE treatment alone can cause sig-
nificant tumor growth retardation which may be due to
its proven activities such as anti-oxidation and induction
of apoptosis, our observations show more important
clinical correlations when a conventional anti-hormone
treatment such as TAM is administered with GE. We
noticed that short-term dietary GE administration only
induced a limited increase of ERα expression in mouse
xenografts, which may suggest a potential quantity con-
trol of ERα expression by GE since this slight ERα incre-
ment may resensitize TAM treatment but avoid
uncontrolled cell proliferation caused by ERα over-
expression [45]. Furthermore, long-term consumption of
GE diet resulted in a relatively large elevation of ERα ex-
pression in spontaneous breast tumors suggesting a pro-
tective effect of GE for prevention of ERα-negative
breast cancer and a subsequent increment of TAM sen-
sitivity by early reversing ERα signaling. Our further
observations on selective epigenetic gene expression
profiles as well as key epigenetic enzymatic activities in
mouse tumors indicate that epigenetic control also plays
an important role during this process, which is consist-
ent with our findings in the cellular system. These data
provide an important clinical implication for the benefi-
cial effects of dietary soybean products on chemopreven-
tion of refractory hormone-resistant breast cancer and
favorable interaction with the treatment benefits of anti-
hormone therapeutic agents.
Conclusions
Collectively, our findings suggest an important role of
soybean genistein (GE) on the resensitization to anti-
hormone therapy of TAM by inducing functional ERα
reactivation in ERα-negative breast cancer through, at
least in part, epigenetic mechanisms. The concentration
of GE we used for in vitro and in vivo studies is safe and
physiologically available, which could be potentially used
in future human studies. The involvement of epigenetic
control of GE in regulating ERα expression is novel and
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may provide new avenues for potential epigenetic ther-
apy in ERα-negative breast cancer. Moreover, the subse-
quent function of GE in prevention breast cancer and
resensitizing the traditional TAM treatment via ERα is
very important since it may provide new preventive and
therapeutic strategies for ERα-negative breast cancer as
well as refractory triple-negative breast cancer (ER,
PGR and HER2/neu negative). In conclusion, our find-
ings provide useful observations relevant to clinical
prevention and therapeutic application for de novo
hormone-resistant breast cancer patients. It provides
novel preventive and therapeutic approaches targeting
ERα reactivation through selective consumption of the
natural dietary ingredient, GE, combined with anti-
hormone therapeutic agents against hormone-resistant
breast cancer. Future efforts aimed at human clinical
trials are urgently needed to lead the applicability of
these novel approaches.
Additional files
Additional file 1: GE and TSA synergistically induced ERα re-
expression in ERα-negative MDA-MB-157 breast cancer cells, but
caused no toxicity in normal HMECs cells. A) Graphic presentation of
dose-dependent ERα expression by GE treatment. MDA-MB-157 cells
were plated in 96-well plates in triplicate and exposed to various
concentrations of GE for 3 days. B) ERα expression changes by the
combined treatment of GE with 5-aza (left) and TSA (right). The MDA-MB-
157 cells were treated with or without either 25 μM GE or 2 μM 5-aza
and 100 ng/ml TSA alone or together for 3 days. Control cells were
grown in parallel with the treated cells but received vehicle DMSO.
Quantitative real-time PCR was performed to measure relative
transcription of ERα. Data are in triplicate from three independent
experiments and were normalized to GAPDH and calibrated to levels in
untreated samples. C) GE and TSA treatment on normal human breast
HMECs cells. HMECs cells were treated with 25 μM GE and 100 ng/ml
TSA alone or together for 3 days as described above. Cellular viability was
measured by MTT assay. Data are in triplicate from three independent
experiments and were normalized to levels in control samples. Columns,
mean; Bars, SD; *, P < 0.05, * * P< 0.001, significantly different from
control; £, P < 0.05, significantly different from GE; †, P < 0.05, significantly
different from 5-aza or TSA.
Additional file 2: Reactivated ERα potentiates the anti-cancer
efficacy of GE and TAM. A) ERα presence affects GE and/or TAM-
induced cellular growth inhibition. MDA-MB-231 cells were transfected
with ERα RNAi for two days and then plated in 96-well plates in triplicate
and exposed to various concentrations of GE and/or TAM for another 3
days. Cellular viability was measured by MTT assay. B) ERα expression
verification after ERα silencing treatment. MDA-MB-231 cells were treated
as described above and parallel mRNAs were collected for ERα
expression. C) ERα expression changes in response to GE and TAM
treatment. MDA-MB-231 cells were treated with 25 μM GE and/or 1 μM
TAM as described in Materials and methods. Quantitative real-time PCR
was performed to measure relative transcription of ERα. Data are in
triplicate from three independent experiments and were normalized to
GAPDH and calibrated to levels in untreated samples. Columns, mean;
Bars, SD; *, P < 0.05, * * P< 0.01, significantly different from control.
Abbreviations
GE: Genistein; ER: Estrogen receptor; TSA: Trichostatin A; 5-aza: 5-aza-2’-
deoxycytidine; TAM: Tamoxifen; PGR: Progesterone receptor; HDACs: Histone
deacetylases; DNMTs: DNA methyltransferases; ChIP: Chromatin
immunoprecipitation.
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